Skip to main content

Table 4 Univariate and multivariate analyses for DFS in MM patients

From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients

Items Univariate Multivariate
HR 95% CI P value HR 95% CI P value
HCV status 0.741 0.462, 1.189 0.214 0.797 0.386, 1.645 0.540
Age (≥ 65 vs. < 65) 1.545 0.553, 4.315 0.407 1.782 0.340, 9.337 0.494
Gender (male vs. female) 1.003 0.613, 1.643 0.989 0.986 0.429, 2.262 0.973
ISS stage 0.865 0.615, 1.214 0.406 1.367 0.558, 3.352 0.494
β2m (≥ 3.5 vs. < 3.5 mg/L) 0.941 0.475, 1.863 0.861 0.329 0.057, 1.89 0.213
Albumin (< 3.5 vs ≥ 3.5 g/L) 1.058 0.639, 1.749 0.827 1.282 0.504, 3.262 0.602
Hemoglobin (< 10 vs. ≥ 10 g/dL) 0.592 0.361, 0.970 0.037* 0.604 0.284, 1.287 0.191
Platelets (< 100 vs. ≥ 100 × 109/L) 0.780 0.385, 1.579 0.490 0.784 0.072, 7.763 0.808
Serum calcium (≥ 12 vs. < 12 mg/dL) 3.253 0.767, 13.795 0.110 7.042 1.12, 44.45 0.038*
Serum creatinine (≥ 2.0 vs. < 2.0 mg/dL 1.123 0.534, 2.362 0.760 0.741 0.162, 3.384 0.699
Serum ALT (abnormal vs. normal) 0.973 0.236, 4.003 0.969 -- -- --
Serum AST (abnormal vs. normal) 1.055 0.545, 2.042 0.874 0.472 0.125, 1.782 0.268
Serum T. bil. (abnormal vs. normal) 1.902 1.034, 3.50 0.039* 10.94 2.92, 41.02 < 0.001*
  1. HR hazard ratio, CI confidence interval, HCV hepatitis C virus, β2m beta-2-microglobulin, ISS International Staging System, ALT alanine transaminase, AST aspartate aminotransferase, T.bil total bilirubin
  2. *Significant at p ≤ 0.05